Omentin-1 inhibits the development of benign prostatic hyperplasia by attenuating local inflammation.

Yi-Yi WangGuo-Qiang ZhuKun XiaHong-Bo ZengYun-Hui HeHui XieZhen-Xing WangRan Xu

Published in: Molecular medicine (Cambridge, Mass.) (2024)

The study demonstrates that ITLN-1 plays a significant role in inhibiting the development of BPH by reducing local inflammation in the prostate gland. These findings highlight the potential of ITLN-1 as a therapeutic target in the management of BPH.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
oxidative stress
prostate cancer
signaling pathway
climate change